David O'Hagan

Member for 40 weeks 2 days

Bio

David O'Hagan Ph.D. d_ohagan@yahoo.com Education: B.S. Biophysics, Wayne State University1994-1995, (Lawrence Tech. University 1991-1994) Ph.D. Molecular Medicine and Genetics, Wayne State University 7/19/2002 Experience: 2006-Present: Biotech Specialist, Sigma-Aldrich, Saint Louis, MO Sigma-Aldrich is a worldwide supplier of molecular biology reagents. 2004-2006: Founder, Ampliprot LLC and Staff Scientist, Burnham Institute, la Jolla, Ca Ampliprot was founded to provide a vehicle for commercialization of a novel protein-PCR, to be distributed by Stratagene if made marketable. This work was done in collaboration with the Burnham Institute. Negotiated ~$150K for phase I testing, details upon request. 2003-2004: Product Manager, Microarray and Proteomics, Stratagene, La Jolla, CA Recruited to participate in the launch of new genomic and proteomic products that are likely to pioneer the next phase of research. Realigned Stratagene’s microarray program to significantly increase market penetration. Instrumental in the acquisition of several large accounts critical for growth. Launched Prolytica, a novel isotopic labeling kit that is the flagship product in Stratagene’s proteomic initiative 2002-2003: Post Doctoral Fellowship, Burnham Institute, La Jolla, California Worked with Eileen Adamson in the area of transcriptional regulation networks, as they apply to breast and prostate cancer using her patented promoter array technology. Developed a database of promoter sequences, used data-mining techniques to characterize promoters that contained known regulatory sequences. Developed PCR conditions and Batch processing of thousands of promoter sequences for the use on promoter microarrays. Used clustering algorithms to data-mine for molecular pathway associations/identification. Used Chromosome immunoprecipitation to identify direct target Interactions based on the transcription factor EGR1, known to be alternatively regulated in breast and prostate cancers. 1999-2002: Founder and Science Officer, Streamline Proteomics (partly owned by Genomic Solutions), Birmingham, Michigan This was a four-person start-up that successfully raised $750K since 2001. Selling the technology concept to local VC, leading to funding Business plan, marketing, and business development efforts targeted toward funding and technology transfer. New Product Development: Proteomics and Genomic Analyzer: a novel protein and DNA analyzer that was based on microsphere flow cytometry. Developed six prototype instruments, three of my own design -High throughput thermal cycler (FastAmp1920), -A micro fluidic flow cytometer chip [microfluidics], -The “VeriArray.” A variable microsphere array system BioAnayzer: instrument to discriminate between microspheres dyed with non-fluorescent coloring agents, followed by the detection of fluorescently bound ligands, or sorted sequentially to a mass spectrometer for peptide sequence identification. VeriArray: is a microsphere array based on polystyrene microspheres doped with non-fluorescent dyes used in hybridization to fluorescently labeled samples to determine differential expression. 1997 – 1999: Staff Scientist, Genomic Solutions, Ann Arbor, Michigan (formerly BioImage) Sales support. A team approach used to sell to installed base. Managed the successful development and launch of the GeneTac System products (Hybridization Station, Flexys Spotter, GeneTac 1000 microarray imager [optics training]) Patent Applications: April 2000: Apparatus And Methods For Assays Of One Or More Analytes January 2002: Variable Microarray And Methods Of Detecting One Or More Analytes Awatramani R, Scherer S, Grinspan J, Collarini E, Skoff R, O'Hagan D, Garbern J, Kamholz J. Evidence that the homeodomain protein Gtx is involved in the regulation of oligodendrocyte myelination. J Neurosci. 1997 Sep 1;17(17):6657-68 Acsadi G, O'Hagan D, Lochmuller H, Prescott S, Larochelle N, Nalbantoglu J, Jani A, Karpati G. Interferons impair early transgene expression by adenovirus-mediated gene transfer in muscle cells. J Mol Med. 1998 May;76(6):442-50. O’Hagan D, Czarnik A, Mei H, eds. Functional Genomics. Integrated Drug Discovery Technologies. New York: Marcel Dekker, June 2002 Adamson E, De Belle I, Mittal S, Wang Y, Hayakawa J, Korkmaz K, O'Hagan D, McClelland M, Mercola D. Egr1 signaling in prostate cancer. Cancer Biol Ther. 2003 Nov-Dec;2(6):610-6. O’Hagan D, Liang H, Partridge J, Mercola D, Adamson D. Egr1 Variable Target Identification in MCF7 Cells using Promoter Arrays. Manuscript in process. Articles: -Streamline gets a bead on Genomics Market, Genome Technology Journal, Nov 2001, No. 15,26 -http://medc.michigan.org/cm/attach/2BF219D6-D66B-479F-9099-1ECB26E95651/381-LS_broch.pdf -http://detnews.com/2002/business/0202/23/business-424746.htm -http://www.michbio.org/news/index.php?content=member_news -http://www.muci.org/Incubation/newsletters/n200207.pdf -http://www.umich.edu/~cvpumbs/calendar/symp02co.html -From the Burnham Institute, Prosiris Pops Up, Genome Technology Journal, Sept. 2003,No. 37,18&20 Posters and Presentations 2003- GSAC, Savanna Georgia, Poster 2001- Bio IT World, Boston, Mini Session 1999- International Biotechnology Conference, Mini Session 1998 – Miptech, Poster

Favorites List